Mark De Boer

Title: The Innovations of Mark De Boer

Introduction

Mark De Boer is a notable inventor based in Blaricum, Netherlands. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies that enhance immune responses. With a total of three patents to his name, De Boer continues to push the boundaries of scientific innovation.

Latest Patents

Among his latest patents is a groundbreaking invention related to gene constructs coding for CD40-binding activating antibodies. This patent discloses agonist anti-CD40 molecules, including monoclonal antibodies that can bind to and stimulate both professional and non-professional human antigen-presenting cells (APCs). These antibodies enhance the stimulatory effect of CD40L on CD40 positive cells and induce phenotypical maturation of monocyte-derived dendritic cells. Several such monoclonal antibodies have been provided, and the cell lines producing them have been deposited at the American Type Culture Collection.

Career Highlights

Mark De Boer is currently associated with Pangenetics B.V., where he applies his expertise in immunology and biotechnology. His work focuses on developing innovative solutions that can potentially transform therapeutic approaches in medicine. His contributions have been recognized within the scientific community, and he continues to be an influential figure in his field.

Collaborations

De Boer collaborates with esteemed colleagues, including David R. Thomas and Pieter C. J. M. Res. These partnerships enhance the research and development efforts at Pangenetics B.V., fostering an environment of innovation and discovery.

Conclusion

Mark De Boer exemplifies the spirit of innovation in biotechnology through his patents and collaborative efforts. His work on CD40-binding activating antibodies holds promise for advancing therapeutic strategies in immunology.